Cargando…

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer

Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Shinichi, Maimaiti, Maihulan, Xu, Minhui, Kamada, Shuhei, Yamada, Yasutaka, Kitoh, Hiroki, Matsumoto, Hiroaki, Takeuchi, Nobuyoshi, Higuchi, Kosuke, Uchida, Haruhito A., Komiya, Akira, Nagata, Maki, Nakatsu, Hiroomi, Matsuyama, Hideyasu, Akakura, Koichiro, Ichikawa, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518240/
https://www.ncbi.nlm.nih.gov/pubmed/30978937
http://dx.doi.org/10.3390/jcm8040489
_version_ 1783418419194888192
author Sakamoto, Shinichi
Maimaiti, Maihulan
Xu, Minhui
Kamada, Shuhei
Yamada, Yasutaka
Kitoh, Hiroki
Matsumoto, Hiroaki
Takeuchi, Nobuyoshi
Higuchi, Kosuke
Uchida, Haruhito A.
Komiya, Akira
Nagata, Maki
Nakatsu, Hiroomi
Matsuyama, Hideyasu
Akakura, Koichiro
Ichikawa, Tomohiko
author_facet Sakamoto, Shinichi
Maimaiti, Maihulan
Xu, Minhui
Kamada, Shuhei
Yamada, Yasutaka
Kitoh, Hiroki
Matsumoto, Hiroaki
Takeuchi, Nobuyoshi
Higuchi, Kosuke
Uchida, Haruhito A.
Komiya, Akira
Nagata, Maki
Nakatsu, Hiroomi
Matsuyama, Hideyasu
Akakura, Koichiro
Ichikawa, Tomohiko
author_sort Sakamoto, Shinichi
collection PubMed
description Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan–Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan–Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients.
format Online
Article
Text
id pubmed-6518240
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65182402019-05-31 Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer Sakamoto, Shinichi Maimaiti, Maihulan Xu, Minhui Kamada, Shuhei Yamada, Yasutaka Kitoh, Hiroki Matsumoto, Hiroaki Takeuchi, Nobuyoshi Higuchi, Kosuke Uchida, Haruhito A. Komiya, Akira Nagata, Maki Nakatsu, Hiroomi Matsuyama, Hideyasu Akakura, Koichiro Ichikawa, Tomohiko J Clin Med Article Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan–Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan–Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients. MDPI 2019-04-11 /pmc/articles/PMC6518240/ /pubmed/30978937 http://dx.doi.org/10.3390/jcm8040489 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sakamoto, Shinichi
Maimaiti, Maihulan
Xu, Minhui
Kamada, Shuhei
Yamada, Yasutaka
Kitoh, Hiroki
Matsumoto, Hiroaki
Takeuchi, Nobuyoshi
Higuchi, Kosuke
Uchida, Haruhito A.
Komiya, Akira
Nagata, Maki
Nakatsu, Hiroomi
Matsuyama, Hideyasu
Akakura, Koichiro
Ichikawa, Tomohiko
Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title_full Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title_fullStr Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title_full_unstemmed Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title_short Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
title_sort higher serum testosterone levels associated with favorable prognosis in enzalutamide- and abiraterone-treated castration-resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518240/
https://www.ncbi.nlm.nih.gov/pubmed/30978937
http://dx.doi.org/10.3390/jcm8040489
work_keys_str_mv AT sakamotoshinichi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT maimaitimaihulan higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT xuminhui higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT kamadashuhei higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT yamadayasutaka higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT kitohhiroki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT matsumotohiroaki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT takeuchinobuyoshi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT higuchikosuke higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT uchidaharuhitoa higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT komiyaakira higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT nagatamaki higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT nakatsuhiroomi higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT matsuyamahideyasu higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT akakurakoichiro higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer
AT ichikawatomohiko higherserumtestosteronelevelsassociatedwithfavorableprognosisinenzalutamideandabirateronetreatedcastrationresistantprostatecancer